Published 1 day ago • loading... • Updated 15 hours ago

Revolution Medicines Partners Royalty Pharma

Summary by Pharmaceutical-technology.com

Revolution Medicines has partnered Royalty Pharma for $2bn to support development and commercialisation of its RAS(ON) inhibitors.

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All

Left

Center

Right

pharmaceutical-technology.com

Revolution Medicines partners Royalty Pharma

Revolution Medicines has partnered Royalty Pharma for $2bn to support development and commercialisation of its RAS(ON) inhibitors.

15 hours ago

Read Full Article

endpoints.news

Revolution inks up to $2B 'flexible' funding deal to advance RAS inhibitor pipeline

Revolution Medicines has signed a “flexible funding agreement” with Royalty Pharma for up to $2 billion that should support it through late-stage development of its lead RAS inhibitor and beyond. The deal consists of two ...

1 day ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right